Your browser does not support javascript:   Search for gard hereSearch for news-and-events here.

Diseases

Genetic and Rare Diseases Information Center (GARD)

Chronic inflammatory demyelinating polyneuropathy


Other Names for this Disease
  • CIDP
  • Chronic Inflammatory Demyelinating Polyradiculoneuropathy
See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.

Treatment

Newline Maker

How might chronic inflammatory demyelinating polyneuropathy (CIDP) be treated?

The standard therapies for CIDP appear to be equally effective and include:[1][2]
  • intravenous immune globulin (IVIG) - adds large numbers of antibodies to the blood plasma to reduce the effect of the antibodies that are causing the problem
  • glucocorticoids - help reduce inflammation and relieve symptoms
  • plasma exchange - remove antibodies from the blood
The treatment choice is influenced by the preference of the affected person, side effects, treatment cost, duration, ease of administration, and availability.[1] Advantages and disadvantages of standard therapies may include the following:
  • IVIG and plasma exchange may lead to a more rapid improvement in CIDP than glucocorticoid therapy, but are less likely than glucocorticoids to produce a remission
  • IVIG is expensive, and its supply is sometimes limited
  • Glucocorticoids are inexpensive, but chronic use is limited by common and important side effects
  • Plasma exchange is expensive, invasive, and available only at specialized centers[1]
Other medications that suppress the immune system (immunosuppressants) may also be used. Physiotherapy may improve muscle strength, function and mobility.[3]
Last updated: 11/23/2015

References
  1. Richard A Lewis. Chronic inflammatory demyelinating polyneuropathy: Treatment and prognosis. UpToDate. Waltham, MA: UpToDate; October, 2015;
  2. Chronic inflammatory polyneuropathy. MedlinePlus. July 27, 2014; https://www.nlm.nih.gov/medlineplus/ency/article/000777.htm.
  3. NINDS Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Information Page. NINDS. November 6, 2015; http://www.ninds.nih.gov/disorders/cidp/cidp.htm.


GARD Video Tutorial

  • Finding Treatment Information - A video developed by GARD Information Specialists that explains how you can find information about treatment for a rare disease.

    Finding Treatment Information

Clinical Trials & Research for this Disease

  • ClinicalTrials.gov lists trials that are studying or have studied Chronic inflammatory demyelinating polyneuropathy. Click on the link to go to ClinicalTrials.gov to read descriptions of these studies.

Medical Products

The medication(s) listed in the table(s) below have been approved by the Food and Drug Administration (FDA) for treatment of this condition. The FDA Office of Orphan Products Development designates "orphan products" for those that treat rare diseases affecting fewer than 200,000 Americans. The table(s) below may not be an exhaustive list of drugs or products used to treat this condition. There may be other products available that are not considered orphan products. To search for all FDA approved drugs, visit Drugs@FDA. You can find orphan products used to treat other conditions by searching the Orphan Drug Product Designation database.


Generic Name Immune Globulin (Human)
Trade Name
(Manufacturer Name)
Gamunex®
(Talecris)
Indication
The FDA has approved this product to be used in this manner.
Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) to improve neuromuscular disability and impairment and for maintenance therapy to prevent relapse
More Information about this product Drug Information Portal
Medline Plus Health Information

Other Names for this Disease
  • CIDP
  • Chronic Inflammatory Demyelinating Polyradiculoneuropathy
See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.